elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Glutamate carboxypeptidase II
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Glutamate carboxypeptidase II
RIS
0.004
(Research Intensity Score)
Papers
554
Top papers
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
2023 · 281 citations
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
2023 · 290 citations
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging
2025 · 62 citations
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
2023 · 115 citations
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
2021 · 365 citations
177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
2025 · 24 citations
Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591
2023 · 70 citations
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
2019 · 962 citations
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
2021 · 185 citations
Newest papers
PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions
2026 · 5 citations
Linker Manipulation with Beta 3 ‐Amino Acids Potentiates the Efficacy and Safety of PSMA Radiopharmaceuticals
2026 · 4 citations
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings
2026 · 2 citations
Prostate-specific membrane antigen theranostics in current clinical use
2026
Theranostic Potential of 177Lu-TLX591 with Best Standard-of-Care and 68Ga-PSMA-11 PET for Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 1 ProstACT SELECT Trial
2026
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED THERAPIES IN THE TREATMENT OF PROSTATE CANCER: ADVANCES, EFFICACY, AND FUTURE DIRECTIONS
2026
The Past, Present, and Future of PSMA-Targeted Therapies in Prostate Cancer
2026
Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report
2026
Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics
2026 · 1 citations
Browse all papers →
Glutamate carboxypeptidase II's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Glutamate carboxypeptidase II's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link